drugset
drugset / Trial / NCT07156578

A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

NCT07156578 ↗

Phase 2 Enrolling by invitation 25 enrolled Rhythm Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a long-term, open-label extension study of bivamelagon in participants with Hypothalamic Obesity (HO) who have transitioned from the index study, LG-MCCL005. The study will last up to 2 years.

Timeline

Start
2025-11-10
Primary completion
2028-04-15
Completion
2028-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Bivamelagon Small molecule — Oral

Indications

acquired hypothalamic obesity